Beigene(06160.HK) (BGNE.US) announced that its new flagship base in the Hopewell Princeton West Innovation Park in New Jersey, USA was officially launched on the 23rd.

Beigene stated that the base covers an area of ​​approximately 0.17 million square meters, with an investment of US$0.8 billion and a construction period of three years. It has world-class biopharmaceutical production capacity and a clinical research and development center. It is expected to enhance the company's differentiation and competitiveness as an innovative company in tumor treatment, and provide flexibility for the scale production of existing and future innovative drugs. The exclusive commercial biopharmaceutical production area covers approximately 0.037 million square meters, with reserved space for future expansion.

Co-founder, director, chairman and CEO Ouyang said that in the future, it will deepen its relationship with major regional research institutions to promote next-generation hematology and solid tumor drug pipelines.